Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
about
The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary DiseasePharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewRationale for a redundant formulary. The Hawthorne effect and the art of medicine.Adherence to GOLD guidelines in real-life COPD management in the Puglia region of Italy
P2860
Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Monotherapy with indacaterol o ...... three large phase III trials.
@ast
Monotherapy with indacaterol o ...... three large phase III trials.
@en
type
label
Monotherapy with indacaterol o ...... three large phase III trials.
@ast
Monotherapy with indacaterol o ...... three large phase III trials.
@en
prefLabel
Monotherapy with indacaterol o ...... three large phase III trials.
@ast
Monotherapy with indacaterol o ...... three large phase III trials.
@en
P2093
P1433
P1476
Monotherapy with indacaterol o ...... three large phase III trials.
@en
P2093
David Lawrence
David Young
Jadwiga A Wedzicha
Roland Buhl
P304
P356
10.1016/J.RMED.2014.10.011
P577
2014-10-27T00:00:00Z